| __timestamp | Dyne Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 179279000 |
| Thursday, January 1, 2015 | 2028000000 | 186359000 |
| Friday, January 1, 2016 | 2281000000 | 171785000 |
| Sunday, January 1, 2017 | 2932000000 | 208136000 |
| Monday, January 1, 2018 | 24000 | 198405000 |
| Tuesday, January 1, 2019 | 271000 | 224169000 |
| Wednesday, January 1, 2020 | 700000 | 245044000 |
| Friday, January 1, 2021 | 1088000 | 252314000 |
| Saturday, January 1, 2022 | 3345000 | 268225000 |
| Sunday, January 1, 2023 | 2461000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc. offer a fascinating glimpse into this dynamic. From 2014 to 2023, Taro's cost of revenue has shown a steady increase, peaking at approximately 324 million in 2023, marking a 70% rise from 2014. In contrast, Dyne Therapeutics experienced a dramatic fluctuation, with costs soaring to nearly 2.9 billion in 2017 before plummeting to just over 2 million in 2023. This stark contrast highlights the volatility and unpredictability in pharmaceutical expenses. Notably, Dyne's data for 2024 is missing, suggesting potential shifts or strategic changes. These insights underscore the importance of strategic financial planning in navigating the complex landscape of pharmaceutical costs.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Amgen Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Pharming Group N.V. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: CRISPR Therapeutics AG vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored